Javascript must be enabled to continue!
Upgrade pacemaker to CRT: predictors and the importance of LVEF
View through CrossRef
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Nowadays 10-15% of CRT implantaon is upgrading from paents (pts) with pacemaker (PMK) who develop reduced LVEF and worsening symptoms from HF. There are few retrospecve studies showing some predictors of pts with single or dual chamber PMK that may need upgrade to CRT, but it is not completely established which pts may benefit the most.
Purpose
To identify predictors at follow-up of upgrading pacemaker to CRT in a population with pacemaker implantation.
Methods
Single center case-control study of pts that performed upgrading to CRT-pacemaker (CRT-P) in our hospital. We excluded pts that performed upgrade to CRT-D. We compare to a PMK populaon matched to age at implantaon and cause of PMK implantaon. Demographic, clinic and electrocardiographic (ECG) data were considered at baseline. Echocardiographic evaluation was performed before pacemaker/CRT upgrading implantaon and at follow-up. Predictors of upgrading were evaluated by the Cox regression. Prognosc impact of LVEF was evaluated as upgrading to CRT-P by Kaplan-Meier curves.
Results
We included 71 pts that performed CRT-P upgrade (mean age 77±10; 49,6% male, mean LVEF before PMK 54.9±9.2%) and 71 pts with pacemaker implantaon (mean age 78 ± 11; 50,4% male; mean LVEF 60.9±7.2%). The clinical characteriscs, ECG and echocardiographic were similar between pacemaker and CRT-P-upgrade, except atrial fibrillaon being more prevalent in PMK group (57.5% vs 42.5% p=0.039). Mortality was not different duringfollow-up between the two groups. In univariate analysis, QRS duraon (PMK: 115ms vs upgrade CRT-P: 132 ms, p=0.038), LVEF (PMK: 60.9% vs upgrade CRT-P: 54.9%, p=0.002) and LV end-diastolic diameter (LVEDD) (PMK: 48.9.4 ± 6.6mm vs upgrade CRT-P: 56.4 ± 6.6mm, p=0.001), LV end-sistolic diameter (LVESD) (PMK: 29.5 ± 6.5mm vs upgrade CRT-P: 37.9 ± 9 mm, p=0.006) were associate to upgrading to CRT. In our population, the unique independent predictor was lower LVEF(Long Rank 6.108, p=0.013) – Figure 1. The best LVEF cut- off to predict upgradingto CRT was 55% (AUC 0.954, sensitivity 64%, specificity 84%) – Figure 2.
Conclusion
In our populaon of CRT upgrading pts, a broad QRS duraon, lower LVEF and a higher LVEDD and LVESD were associated to upgrade to CTR-P. We try to establish a new value for LVEF that could lead to upgradingto CRT-P, and maybe the classical cut-off of 50% should be reviewed.
Oxford University Press (OUP)
Title: Upgrade pacemaker to CRT: predictors and the importance of LVEF
Description:
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Nowadays 10-15% of CRT implantaon is upgrading from paents (pts) with pacemaker (PMK) who develop reduced LVEF and worsening symptoms from HF.
There are few retrospecve studies showing some predictors of pts with single or dual chamber PMK that may need upgrade to CRT, but it is not completely established which pts may benefit the most.
Purpose
To identify predictors at follow-up of upgrading pacemaker to CRT in a population with pacemaker implantation.
Methods
Single center case-control study of pts that performed upgrading to CRT-pacemaker (CRT-P) in our hospital.
We excluded pts that performed upgrade to CRT-D.
We compare to a PMK populaon matched to age at implantaon and cause of PMK implantaon.
Demographic, clinic and electrocardiographic (ECG) data were considered at baseline.
Echocardiographic evaluation was performed before pacemaker/CRT upgrading implantaon and at follow-up.
Predictors of upgrading were evaluated by the Cox regression.
Prognosc impact of LVEF was evaluated as upgrading to CRT-P by Kaplan-Meier curves.
Results
We included 71 pts that performed CRT-P upgrade (mean age 77±10; 49,6% male, mean LVEF before PMK 54.
9±9.
2%) and 71 pts with pacemaker implantaon (mean age 78 ± 11; 50,4% male; mean LVEF 60.
9±7.
2%).
The clinical characteriscs, ECG and echocardiographic were similar between pacemaker and CRT-P-upgrade, except atrial fibrillaon being more prevalent in PMK group (57.
5% vs 42.
5% p=0.
039).
Mortality was not different duringfollow-up between the two groups.
In univariate analysis, QRS duraon (PMK: 115ms vs upgrade CRT-P: 132 ms, p=0.
038), LVEF (PMK: 60.
9% vs upgrade CRT-P: 54.
9%, p=0.
002) and LV end-diastolic diameter (LVEDD) (PMK: 48.
9.
4 ± 6.
6mm vs upgrade CRT-P: 56.
4 ± 6.
6mm, p=0.
001), LV end-sistolic diameter (LVESD) (PMK: 29.
5 ± 6.
5mm vs upgrade CRT-P: 37.
9 ± 9 mm, p=0.
006) were associate to upgrading to CRT.
In our population, the unique independent predictor was lower LVEF(Long Rank 6.
108, p=0.
013) – Figure 1.
The best LVEF cut- off to predict upgradingto CRT was 55% (AUC 0.
954, sensitivity 64%, specificity 84%) – Figure 2.
Conclusion
In our populaon of CRT upgrading pts, a broad QRS duraon, lower LVEF and a higher LVEDD and LVESD were associated to upgrade to CTR-P.
We try to establish a new value for LVEF that could lead to upgradingto CRT-P, and maybe the classical cut-off of 50% should be reviewed.
Related Results
Calreticulin Promotes Immunity Against Acute Myeloid Leukemia Cells in Vivo
Calreticulin Promotes Immunity Against Acute Myeloid Leukemia Cells in Vivo
Abstract
Pre-apoptotic cancer cells release internalized calreticulin (CRT) to their surface prior to death, which acts as an ‘eat-me’ signal to local phagocytes. Ch...
Autonomic nervous system driven resynchronization therapy using left ventricular only pacing with electrocardiographic optimization. A new paradigm. 9+ month follow-up of dual chamber systems
Autonomic nervous system driven resynchronization therapy using left ventricular only pacing with electrocardiographic optimization. A new paradigm. 9+ month follow-up of dual chamber systems
Abstract
Background
LV-only (LVo) CRT was recognized in the 2013 ESC guidelines [1] as non-inferior to biventricular (biV) CRT i...
Clinical Characteristics and Outcomes of Older Cardiac Resynchronization Therapy Recipients Using a Pacemaker versus a Defibrillator
Clinical Characteristics and Outcomes of Older Cardiac Resynchronization Therapy Recipients Using a Pacemaker versus a Defibrillator
CRT‐P versus CRT‐D OutcomesBackgroundCardiac resynchronization therapy (CRT) is commonly used to manage heart failure, yet published guidelines do not distinguish between recommend...
Incremental prognostic value of fully automatic LVEF measured at stress using machine learning
Incremental prognostic value of fully automatic LVEF measured at stress using machine learning
Abstract
Background
Cardiovascular magnetic resonance (CMR) is the gold standard to measure left ventricular ejection fraction (...
Beta-blocker use is associated with prevention of left ventricular remodeling in recovered dilated cardiomyopathy
Beta-blocker use is associated with prevention of left ventricular remodeling in recovered dilated cardiomyopathy
Abstract
Background
Withdrawal of optimal medical therapy has been reported to relapse cardiac dysfunction in patients with dila...
Cardiac resynchronization therapy: better in women?
Cardiac resynchronization therapy: better in women?
Abstract
Introduction
Women are underrepresented in cardiac resynchronization trials; however, they have been shown to de...
Comparison of de novo and upgrade to resynchronization therapy: a propensity-score matched analysis
Comparison of de novo and upgrade to resynchronization therapy: a propensity-score matched analysis
Abstract
Background
Upgrade to resynchronization therapy (CRT) from conventional pacemaker (P) or defibrillator (D) is common pr...
Left-ventricular-only cardiac resynchronization therapy with electrocardiographic optimization: 100-day follow-up
Left-ventricular-only cardiac resynchronization therapy with electrocardiographic optimization: 100-day follow-up
Abstract
Background
LV-only (LVo) cardiac resynchronization therapy (CRT) was recognized in 2013 as a non-inferior alternative t...

